Xbiotech announces first subject enrollment in phase i clinical trial for hutrukin, a novel candidate therapy for stroke

Hutrukin, a therapy discovered and manufactured at xbiotech, is aimed to reduce brain injury after stroke hutrukin, a therapy discovered and manufactured at xbiotech, is aimed to reduce brain injury after stroke

XBIT Ratings Summary

XBIT Quant Ranking